Slate Medicines
Founded 2025
About Slate Medicines
Slate Medicines develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention.
Company Facts
- Founded: 2025
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $130.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2026)
- Website: https://www.slatemedicines.com
Social Profiles
Canonical: https://fsome.com/organization/slate-medicines-12412404 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.